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Guided Cardiopoiesis Enhances Therapeutic Benefit
of Bone Marrow Human Mesenchymal Stem Cells
in Chronic Myocardial Infarction
Atta Behfar, MD, PHD,* Satsuki Yamada, MD, PHD,* Ruben Crespo-Diaz, BS,*
Jonathan J. Nesbitt, BS,* Lois A. Rowe, ASCP,* Carmen Perez-Terzic, MD, PHD,*†
Vinciane Gaussin, PHD,‡ Christian Homsy, MD,‡ Jozef Bartunek, MD, PHD,§ Andre Terzic, MD, PHD*
Rochester, Minnesota; and Mont-Saint-Guibert and Aalst, Belgium
Objectives The goal of this study was to guide bone marrow-derived human mesenchymal stem cells (hMSCs) into a cardiac
progenitor phenotype and assess therapeutic benefit in chronic myocardial infarction.
Background Adult stem cells, delivered in their naïve state, demonstrate a limited benefit in patients with ischemic heart
disease. Pre-emptive lineage pre-specification may optimize therapeutic outcome.
Methods hMSC were harvested from a coronary artery disease patient cohort. A recombinant cocktail consisting of trans-
forming growth factor-beta1, bone morphogenetic protein-4, activin A, retinoic acid, insulin-like growth factor-1,
fibroblast growth factor-2, alpha-thrombin, and interleukin-6 was formulated to engage hMSC into cardiopoiesis.
Derived hMSC were injected into the myocardium of a nude infarcted murine model and followed over 1 year for
functional and structural end points.
Results Although the majority of patient-derived hMSC in their native state demonstrated limited effect on ejection frac-
tion, stem cells from rare individuals harbored a spontaneous capacity to improve contractile performance. This
reparative cytotype was characterized by high expression of homeobox transcription factor Nkx-2.5, T-box tran-
scription factor TBX5, helix–loop–helix transcription factor MESP1, and myocyte enhancer factor MEF2C, mark-
ers of cardiopoiesis. Recombinant cardiogenic cocktail guidance secured the cardiopoietic phenotype across the
patient cohort. Compared with unguided counterparts, cardiopoietic hMSC delivered into infarcted myocardium
achieved superior functional and structural benefit without adverse side effects. Engraftment into murine hearts
was associated with increased human-specific nuclear, sarcomeric, and gap junction content along with induc-
tion of myocardial cell cycle activity.
Conclusions Guided cardiopoiesis thus enhances the therapeutic benefit of bone marrow-derived hMSC in chronic ischemic
cardiomyopathy. (J Am Coll Cardiol 2010;56:721–34) © 2010 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2010.03.066d
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mell-based reparative approaches are increasingly consid-
red in the management of ischemic heart disease. Stem cell
apacity for multilineage tissue specification provides the
pportunity to extend treatment options for ischemic car-
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eart Disease Research Program, Mayo Clinic, Rochester, Minnesota; †Department
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enter, OLV Ziekenhuis, Aalst, Belgium. Supported by National Institutes of Health
grants #HL83439, #HL85208), American Heart Association, Marriott Heart
isease Research Program, Cardio3 BioSciences, Ted Nash Long Life Foundation,
alph Wilson Medical Research Foundation, Mayo Clinic General Mills Clinician-
nvestigator Fellowship, Mayo Graduate School, Mayo Clinic FUTR Career Devel-
pment Award, and Mayo Clinic Discovery Translation Program. Drs. Behfar,
aussin, Homsy, Bartunek, and Terzic serve on the research advisory board of
ardio3 BioSciences.t
Manuscript received August 24, 2009; revised manuscript received March 2, 2010,
ccepted March 9, 2010.iomyopathy beyond current practices and achieve heart
epair (1–3).
See page 735
Emerging experience has focused on adult stem cells
elivered unaltered, in their native state (4,5). Of increased
nterest are mesenchymal stem cells with a documented
ptitude for multipotent differentiation, cytoprotection, and
yocardial restoration demonstrated when derived from
llogeneic healthy donors (6–8). However, in autologous
herapy, patient-related modifiers of regenerative capacity,
ncluding age, sex, and comorbidities, translate into vari-
bility in repair-compromising efficacy (9–11). Develop-
ent of technologies that would enhance stem cell benefit ishus warranted (1–13).
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hMSC Cardiopoiesis for Heart Repair August 24, 2010:721–34We here tracked interpatient
variation in stem cell effectiveness
and identified that expression of
cardiac markers in human mesen-
chymal stem cells (hMSCs) biases
repair. Accordingly, nonreparative
hMSC were guided to acquire re-
generative potency through car-
diogenic priming. Derived cardio-
poietic hMSC demonstrated
improved efficacy compared with
their naïve source, establishing
an adult stem cell– derived pro-
genitor with enhanced benefit
in the treatment of chronic isch-
emic cardiomyopathy.
Methods
Study protocols were approved
by pertinent institutional ethics
committee, institutional review
oard, and institutional animal care and use committee.
schemic heart disease patient cohort. Patients undergo-
ng coronary artery bypass surgery provided informed con-
ent. Information concerning age, sex, history, medications,
erioperative laboratory evaluation, and coronary assess-
ent is presented in Online Tables 1 to 3.
tem cell culture. Human bone marrow aspirates, ob-
ained during coronary artery bypass surgery following
ternotomy, yielded plastic-adherent hMSC with identity
onfirmed by fluorescence-activated cell sorting using the
D34/CD45/CD105/CD133 panel (Online Fig. 1).
ells were cultured at 37°C in advanced minimal essential
edium supplemented with 5% human platelet lysate (14),
nd stimulated with transforming growth factor (TGF)-
eta1 (2.5 ng/ml), bone morphogenetic protein (BMP)-4
5 ng/ml), activin A (5 ng/ml) (15,16), fibroblast growth
actor (FGF)-2 (10 ng/ml) (6), interleukin (IL)-6 (100
g/ml) (17), factor IIa (h-alpha-thrombin, 1 U/ml) (18),
nsulin-like growth factor (IGF)-1 (50 ng/ml) (6), and/or
etinoic acid (1 mol/l) (19). Phospho-Akt inhibition
as achieved with SR13668 (50 nmol/l). Differentiation
eyond the cardiopoietic state was carried out with 1%
latelet lysate in the presence of FGF-2 and h-alpha-
hrombin for 10 days. To scale-up production under good
anufacturing practice (GMP) compliance, cell culture
rocedures were site-certified by independent regulatory
eview as meeting mandatory environmental and quality
ssurance criteria required to ensure traceability, purity,
omogeneity, and sterility for batch testing and release (14).
ibonucleic acid profiling. Real-time quantitative poly-
erase chain reaction (PCR) was performed using a Taq-
an PCR kit (Applied BioSystems, Carlsbad, California)
Abbreviations
and Acronyms
BMP  bone
morphogenetic protein
DNA  deoxyribonucleic
acid
FGF  fibroblast growth
factor
GMP  good manufacturing
practice
hMSC  human
mesenchymal stem cell
IGF  insulin-like growth
factor
IL  interleukin
mRNA  messenger
ribonucleic acid
PCR  polymerase chain
reaction
TGF  transforming growth
factorn triplicate. Threshold cycle (CT) values were determined Asing the 2–CT method, normalized to human-specific
APDH (TaqMan, Applied BioSystems). Genes represen-
ative of cardiac transcriptional activity included homeobox
ranscription factor Nkx-2.5 (Hs00231763_m1), GATA-4
Hs00171403_m1), myocyte enhancer factor MEF2C
Hs00231149_m1), T-box transcription factor TBX5
Hs00361155_m1), FOG-1 (Hs00542350_m1), helix-
oop-helix transcription factor MESP1 (Hs00251489_m1),
ATA-6 (Hs00232018_m1), and Flk-1 (Hs00911699_m1).
rotein and deoxyribonucleic acid probing. Immuno-
taining for cardiac transcription factors MEF2C (1:400, Cell
ignaling Technologies, Danvers, Massachusetts), Nkx-2.5
1:150, Santa Cruz Biotechnology, Santa Cruz, California),
ATA-4 (1:150, Santa Cruz Biotechnology), TBX5 (1:5000,
bcam, Cambridge, Massachusetts), MESP1 (1:250, Novus
iologicals, Upplands Väsby, Sweden), FOG-2 (1:100, Santa
ruz Biotechnology), along with Phospho-AktSer473
1:100, Cell Signaling Technologies), human-specific tro-
onin I (1:100, Abcam), sarcomeric alpha-actinin (1:500,
igma-Aldrich, St. Louis, Missouri), ventricular myosin
ight chain MLC-2V (1:500, Synaptic Systems, Goettin-
en, Germany), Sca-1 (1:100, R&D Systems, Minneapolis,
innesota), CD-31/PECAM-1 (1:500, Beckman Coulter,
rea, California), alpha-smooth muscle actin (1:500,
igma), human lamin A/C (1:50, Novocastra, Leica Micro-
ystems, Bannockburn, Illinois), connexin 43 (1:100,
ymed Laboratories, San Francisco, California), and Ki-67
1:500, NeoMarkers, Thermo Scientific, Fremont, Califor-
ia) was performed following fixation in 3% paraformalde-
yde and permeabilization with 1% Triton X-100 (Sigma).
uman Alu deoxyribonucleic acid (DNA) probing (Bio-
enex, San Ramon, California) required hybridization
85°C, 10 min) and incubation at 37°C overnight followed
y antifluorescein green fluorescent protein–labeled second-
ry detection. For genomic probing, human and murine
NA were labeled in Vysis Spectrum Green or Orange
eoxyuridine triphosphate (Abbott Molecular, Abbott Park,
llinois) via nick translation followed by hybridization and
enaturation. Frozen tissue was fixed (3:1 methanol/acetic
cid), and pre-treated in 2x SSC (15 mM sodium chloride
1.5 mM sodium citrate  2 H2O) for 2 min (73°C),
laced 5 min in 1 mol/l tris, 0.5 mol/l ethylenediamine
etraacetic acid (90°C), 2 min in 4 mg pepsin/l, 0.9% NaCl
37°C), and 30 s in 70% ethyl alcohol. Slides were denatured
n 70% formamide (73°C), followed by a 70%/85%/100%
thyl alcohol series. Denatured genomic probes were applied
o sections, hybridized overnight (37°C), and washed in 2x
SC/0.1% NP40 solution (73°C). Slides were counter-
tained with 4,6-diamino-2-phenylindole (DAPI)–
ontaining mounting medium.
ell imaging. Images were obtained with LSM 510/LSM
00 laser scanning confocal or ApoTome structured illumi-
ation microscopes (Carl Zeiss, Thornwood, New York).
uantification of cytosolic and nuclear induction of Nkx-
.5, MEF2C, or GATA-4 was performed using Zeiss
xioplan and MetaMorph software (Molecular Devices,
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August 24, 2010:721–34 hMSC Cardiopoiesis for Heart Repairunnyvale, California). Cell cycle activity was quantified
sing a hematocytometer. Cell structure was resolved by
ransmission electron microscopy (20). Calcium transients
ere monitored in cells loaded with 5 mol/l of the
alcium-selective probe fluo-4-acetoxymethyl ester (Molec-
lar Probes, Invitrogen, Carlsbad, California) using a tem-
erature controlled Zeiss LSM 510 or ApoTome micro-
cope with line-scan or phase images acquired during 1-Hz
timulation (15).
ell therapy. Myocardial infarction was performed in 8 to
2 weeks old nude, immunocompromised mice (Harlan
aboratories, Indianapolis, Indiana) (21). Following intu-
ation and ventilation under isoflurane anesthesia, proximal
eft anterior descending artery was ligated with 9-0 suture.
njury induced ST-segment changes on electrocardiography
MP150, Biopac, Goleta, California) and akinetic regions
n echocardiography (Sequoia 512, Siemens, Munich, Ger-
any; Vevo2100, VisualSonics, Toronto, Ontario). Follow-
ng a blinded design, 1-month post-infarction hMSC (a
otal of 600,000), suspended in 12.5 l phosphate buffered
aline, were injected under microscopic visualization in 5
picardial sites (120,000 cells per site) in the anterior wall of
he left ventricle. A saline-treated group underwent an
dentical procedure. Left ventricular function and structure
ere serially followed by echocardiography at pre-
nfarction; 1-month after infarction (pre-cell therapy); and
, 2, 6, 12, and 20 months post-cell therapy. Ejection fraction
%) was calculated as: [(LVVd – LVVs)/LVVd] 100, where
VVd is left ventricular end-diastolic volume (l), and
VVs is left ventricular end-systolic volume (l).
tatistics. Data are presented as mean  SD unless oth-
rwise indicated (JMP 8, SAS Institute, Cary, North
arolina). Paired group analysis was performed using Stu-
ent t test for each pair of samples without correction for
ype I error, and nonparametrically validated using Wil-
oxon signed rank test (JMP 8). Kaplan-Meier analysis with
og-rank testing was applied for survival evaluation. A p
alue 0.05 was considered significant.
esults
eparative profile extracted from patient stem cells
emonstrating innate efficacy. Bone marrow-derived
MSC obtained from patients undergoing coronary artery
ypass revealed individuals with an innate capacity for heart
epair. Specifically, hMSC derived from 2 of 11 individuals
ignificantly improved ejection fraction following myocar-
ial injection into a nude murine model of chronic ischemic
ardiomyopathy (Fig. 1A). No clinical features separating
hese patients from the cohort were apparent (Online
ables 1 to 3). Reparative stem cells were distinguished
rom noneffective hMSC counterparts by robust expression
f early (homeobox transcription factor Nkx-2.5 [22],
-box transcription factor TBX5 [23], and the helix–loop–
elix transcription factor MESP1 [24]) and late (myocyte
nhancer factor MEF2C [25]) cardiac transcription factors (Fig. 1B). Distinctive protein abundance was corroborated
n quantitative PCR with a 3- to 6-fold up-regulation in
BX5 and MESP1 and a 2- to 3-fold up-regulation of
EF2C messenger ribonucleic acid (mRNA) in effective
ersus noneffective hMSC, respectively (Fig. 1C). Up-
egulated cardiac transcription factors in hMSC thereby
rovided a molecular signature consistent with ejection
raction improvement.
nduction of cardiac program in hMSC. To impose
xpression and potentiation of cardiac transcription factors,
hile maintaining proliferative status, endoderm-based
athways (26,27) contributing to embryonic cardiogenesis
15,16) were tested on the adult hMSC phenotype (Fig. 2).
he TGF-beta superfamily members (TGF-beta1, BMP-4,
nd activin-A), which induce Nkx-2.5 expression in embry-
nic stem cells (16), here individually promoted cytosolic
kx-2.5 and MEF2C expression at protein (Fig. 2A,
nline Fig. 2A) and mRNA (Online Fig. 2B) levels.
timulation of hMSC with a combination of TGF-beta1,
MP-4, and activin-A resulted in augmented Nkx-2.5 and
EF2C cytosolic expression, further enhanced by retinoic
cid (Fig. 2A, Online Fig. 3). The TGF-beta superfamily
embers and retinoic acid did not achieve nuclear translo-
ation of cardiac transcription factors, maintaining nuclear
o cytosol ratios equivalent to untreated hMSC (Fig. 2B,
rst and second columns). Potentiation of cardiac transcrip-
ion factors was achieved with IGF-1 and FGF-2 whose
ombination triggered nuclear translocation of Nkx-2.5 and
EF2C (Fig. 2B, fifth column, Online Fig. 4), correlating
ith Akt activation (Online Fig. 5) as nuclear expression
as abolished by the Akt inhibitor, SR13668 (Fig. 2B, sixth
olumn, Online Fig. 6). Stimulation of hMSC with TGF-
eta1, BMP-4, activin-A, retinoic acid, FGF-2, and IGF-1
Fig. 2C, Passage 0) compromised cell proliferation, rescued by
lpha-thrombin and IL-6 (Fig. 2C). Applied as a human
ecombinant cardiogenic cocktail, within a 5% platelet lysate at
he onset of a 5-day incubation period, TGF-beta1, BMP-4,
ctivin-A, retinoic acid, FGF-2, IGF-1, alpha-thrombin, and
L-6 induced cardiac transcription factor expression, potenti-
ted nuclear translocation, and maintained cell cycle progres-
ion (Fig. 2D). Induction of procardiogenic transcription
actors was chronicled with mRNA profiling during and after
ocktail exposure (Fig. 2E), and the derived cardiopoietic
rofile stabilized within 5 days was maintained for 7 passages.
ardiogenic cocktail guides cardiopoiesis to yield functional
ardiomyocytes. Guidance with the cardiogenic cocktail in-
uced nuclear translocation of cardiac transcription factors,
ocumented for Nkx-2.5 (86  10% of cells), MEF2C
84 8%), FOG-2 (78 15%), TBX5 (76 7%), MESP1
83  11%), and GATA-4 (81  3%) (5,15,25,28),
ugmenting baseline expression limited to the cytosol in
nguided hMSC (Fig. 3A). In this way, hMSC from each
atient (n  12) were guided to derive a cardiopoietic
henotype with nuclear up-regulation of cardiac transcrip-
ion factors in the absence of sarcomere protein expression
Online Fig. 7A). This lineage engagement was further
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hMSC Cardiopoiesis for Heart Repair August 24, 2010:721–34ocumented with mRNA analysis revealing a 12-, 16-, 6-,
nd 2-fold increase in Nkx-2.5, Flk-1, GATA-6, and
OG-1, respectively in treated versus untreated hMSC
Fig. 3B). Thereby, hMSC from patients with ischemic
eart disease were converted in vitro from a naïve state of
equestered plasticity to active tissue specification adopting
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Figure 1 Repair Efficacy in hMSC Correlates With Cardiac Tran
(A) Patient (Pt)  human mesenchymal stem cells demonstrated variable repair a
lighted) demonstrated benefit. (B) Low expression of cardiac transcription factors
Robust Nkx-2.5 (83  5% and 86  2% of  hMSC in Patients #3 and #9), MEF2
shown, with single channels provided in inset). Bar: 20 m. (C) Reparative patter
cleic acid (mRNA) in reparative versus nonreparative hMSC. AU  arbitrary units; Aphenotype consistent with enhanced repair aptitude. cDifferentiation beyond the cardiopoietic state, in 1%
uman platelet lysate medium, ultimately achieved sarcom-
rogenesis tracked by expression of alpha-actinin (48 10%
f cells at Day 10 and 75  8% at Day 15) and troponin I
75 6% of cells at Day 10 and 86 5% at Day 15), which
emonstrated immature organization at 20-days post-
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reparative  human mesenchymal stem cells (hMSC) (Patient #2 illustrated).
5, and MESP1 expression in  hMSC with reparative capacity (Patient #9
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n valid
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Figure 2 Derivation of Cardiogenic Cocktail That Induces and Potentiates
Cardiac Transcription Factor Expression and Maintains Cell Cycle Activity
(A) Bone morphogenetic protein (BMP)-4, transforming growth factor (TGF)-beta1, and activin-A induced cytosolic expression of Nkx-2.5 and MEF2C (light red). Addition of
retinoic acid (RA) boosted cytosolic induction (red). (B) BMP-4, TGF-beta1, activin-A, and RA (red) potentiated nuclear translocation of Nkx-2.5 and MEF2C when com-
bined with insulin-like growth factor (IGF)-1 and fibroblast growth factor (FGF)-2. Akt inhibitor (SR13668) inhibited nuclear translocation. (C) Low hMSC cell cycle activity
following BMP-4, TGF-beta1, activin-A, retinoic acid, IGF-1, and FGF-2 treatment (blue) rescued by interleukin (IL)-6 and human alpha-thrombin. Brackets indicate pared
analysis. Star and double star: p  0.05. (D) Cardiogenic cocktail, applied as a combined regimen, induced and potentiated nuclear translocation of Nkx-2.5 and
MEF2C while maintaining cell cycle activity. (E) Nkx-2.5, TBX5, MEF2C, GATA-4, GATA-6, FOG-1, and MESP1 hMSC mRNA in response to cocktail treatment. A to C and E
evaluate nonreparative patient hMSC. B/T/A/R  bone morphogenetic protein-4, transforming growth factor-beta1, activin-A, and retinoic acid; EGF  epidermal growth
factor; VEGF  vascular endothelial growth factor; other abbreviations as in Figure 1.
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hMSC Cardiopoiesis for Heart Repair August 24, 2010:721–34uscle actin stained myocytes were rarely observed (1  1%
f cells) at Day 20 of differentiation (Online Fig. 7B).
ascent cardiomyocytes derived from guided hMSC con-
ained 80% of mitochondria with structured cristae and
Unguided
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GuidedA
C
Figure 3 Cardiogenic Cocktail Guides Cardiogenesis to Yield Fu
(A) Nuclear translocation of Nkx-2.5, MEF2C, FOG-2, and GATA-4 in cocktail-guided
mRNA expression of Nkx-2.5, Flk-1, GATA-6, and FOG-1. Star: p  0.01. (C) Cockt
Day 5 (D5) and sarcomerogenesis (alpha-actinin) achieved by Days 15 (D15) to 20
dant nuclei (left), transmission electron microscopy of cocktail-guided hMSC at Da
1 m (upper left); 250 nm (other 3 panels). (E) Calcium transients elicited in responligned with forming sarcomeres, in contrast to unguided mMSC characterized by prominent nuclei and immature
itochondria (Fig. 3D, Online Fig. 7C). At Day 20 (15
ays after the end of cocktail stimulation), functional
xcitation-contraction coupling was documented by rhyth-
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August 24, 2010:721–34 hMSC Cardiopoiesis for Heart Repairponse to external electrical stimulation (Fig. 3E, Online
ideos). Thus, the cardiopoietic phenotype derived from
MSC can yield sarcomere-containing myocytes capable of
lectromechanical response.
ardiopoietic guidance enhances therapeutic efficacy of
MSC. Guided hMSC (n  12) demonstrated on average
3-fold increase in TBX5 and an 8-fold increase in MESP1
nd MEF2C (Fig. 4A). Induction of the cardiopoietic
henotype was verified with real-time quantitative PCR
rior to transplantation into nude mice 1 month after
oronary ligation. Permanent ligation of the left anterior
escending artery induced akinesis and dyskinesis in the
nterior wall (ejection fraction: 78.8  2.1% and 38.2 
.2%, pre- vs. post-infarction, p  0.05) with an 84.6%
urvivorship at 1 month (n  52). Surviving infarcted mice
ere randomized into saline-, naïve hMSC-, and cardio-
oietic hMSC-treatment groups. Direct myocardial delivery
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Figure 4 Cardiopoietic hMSC Phenotype Associated With Eject
(A) Induction of cardiac transcription factors TBX5, MEF2C, and MESP1 mRNA doc
improvement in chronically infarcted mice treated with cardiopoietic over patient-m
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yocardial dysfunction (Fig. 5E), and cachexia observed at
0-month follow-up was typically absent from the cardio-
oietic hMSC-treated group (Fig. 5F). Distinct outcomes
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espectively (Fig. 6D). In contrast to persistent scar and low
uman-troponin staining in the naïve hMSC group, the
nterior wall of cardiopoietic hMSC-treated hearts revealed
uman-specific troponin positive cardiomyocytes (Fig. 6E,
nline Figs. 8B and 8C). Thus, treatment with cardiopoi-
tic hMSC resulted in stable functional and structural
enefits in chronically infarcted hearts.
elivery of cardiopoietic hMSC triggers safe repair.
istological evaluation of murine hearts 48 h after delivery
f fluorochrome-loaded cardiopoietic hMSC-validated epi-
ardial delivery demonstrating cellular implantation (Fig.
A). The hMSC engraftment within treated myocardium,
uantified utilizing a human-specific GAPDH standard
urve derived from murine hearts treated with escalating
oses of hMSC (Fig. 7B), was 3.3  2.8% and 3.4  0.7%
f cells injected for naïve, and 13.8  2.4% and 9.6  1.2%
f cells injected for cardiopoietic hMSC at 3 months and 2
ears, respectively (Fig. 7C). Cardiopoietic hMSC-treated
urine myocardium revealed widespread presence of
uman-derived cells with positive staining for Alu-DNA
equences specific to the human species; the human-derived
ells were absent in saline-treated infarcted controls (Fig.
D). Quantification of human lamin within the infarcted
nterior wall, validated with Alu-DNA staining, revealed
 2% (n  5) versus 25  5% (n  5) of nuclei in naïve
nd cardiopoietic hMSC-treated hearts, respectively (p 
.01). Typically, nuclear fusion was absent in cardiopoietic
MSC-treated hearts as determined by species-specific
NA hybridization, albeit cytosolic fusion could not be
uled out (Fig. 7E; see rare event in Online Fig. 9A).
ardiopoietic hMSC-derived human lamin–positive myo-
ytes integrated with host tissue as demonstrated by colo-
alization with connexin-43, a gap junction protein (Fig.
F). Cardiopoietic hMSC transplantation was thus associ-
ted with long-term cellular retention and nonfusogenic
ntegration within the myocardium. Engrafted cardiopoietic
MSC displayed a ventricular phenotype as counterstaining
f human troponin-positive cells colocalized with ventricu-
ar myosin light chain (MLC-2V) in the resolving scar (Fig.
A, Online Fig. 8B). Within the anterior wall of cardio-
oietic hMSC-treated hearts, colocalization of human car-
iac troponin I with alpha-actinin (Fig. 8B, Online Fig. 8C)
ccounted for 12 3% of cardiomyocytes, in contrast to 2.5
2% of naïve hMSC-treated hearts (Figs. 8B and 8F).
urthermore, human-troponin–positive cardiomyocytes and
djacent murine myocardium in cardiopoietic hMSC-
reated hearts had a significantly higher expression of Ki-67
35 3%) compared with naïve hMSC-treated heart (10
%), indicative of cell cycle engagement of endogenous and
MSC-derived cardiomyocytes up to 3 months after deliv-
ry (Figs. 8B and 8F). Specifically in the cardiopoietic
MSC-treated myocardium, 10  3% of human troponin
nd 3  2% of nonhuman alpha-actinin/MLC-2V positive
ardiomyocytes expressed Ki-67. In addition, nonhuman
ca-1 cells were induced from 5.1  3 to 18.6  5.7 cells eer field in naïve versus cardiopoietic hMSC-treated hearts
Online Figs. 9B and 9C) (29). Cardiopoietic hMSC-
reated myocardium demonstrated vasculogenic potential,
bserved distal to the occluded coronary vessel with expres-
ion of human PECAM-1 (CD-31) (Figs. 8D and 8G) and
olocalization of human lamin with alpha-smooth muscle
ctin (Figs. 8E and 8H). As such, transplanted cardiopoietic
MSC contributed to the myocardial pool, up-regulated cell
ycle activity, induced endogenous Sca-1-positive stem cell
roliferation, and contributed to neovasculogenesis distal to the
ite of ligation. Long-term safety of cardiopoietic hMSC was
ocumented by absence of myocardial tumorigenesis (Online
ig. 10A) or electrical ectopy on electrocardiography (Online
ig. 10B). Beyond the heart, at 1-year follow-up, no evidence
f abnormal cell proliferation or neoplastic transformation was
ound on gross or histological examination of other well-
erfused organs (Online Fig. 10C). Thus, transplantation of
ardiopoietic hMSC achieved lineage specification for safe
epair in the setting of ischemic cardiomyopathy.
caled-up GMP production of cardiopoietic hMSC.
ollowing safety and efficacy testing, the feasibility of
caled-up cardiopoietic hMSC production under GMP
riteria was evaluated (7,14). With regulatory approval,
ardiopoietic guidance was carried out using standard oper-
ting procedures with each cocktail component adhering to
MP guidelines. In this way, 600 million cardiopoietic
MSC were derived within 6 weeks of patient bone marrow
arvest meeting sterility, purity, and homogeneity release
riteria. The GMP-grade cardiopoietic hMSC were suc-
essfully derived from 10 patients and released following
emonstration of cardiac transcription factor up-regulation
onsistent with an aptitude for repair. Thus, guided cardio-
oiesis under GMP stringency demonstrated the capacity
or scalable manufacturing of a stem cell biologics with
mposed cardioreparative traits.
iscussion
eterogeneous outcome among patients treated with autol-
gous stem cells is recognized as an impediment to broader
linical acceptance of cell-based therapy in cardiovascular
edicine (5,9,11,30,31). The present study identified indi-
iduals that harbored hMSC with an innate capacity for
yocardial repair. Reparative stem cells were characterized
y up-regulation of cardiac transcription factors, suggesting
hat pre-emptive cardiogenic specification could ensure
nhanced therapeutic efficacy of hMSC.
Indeed, hMSC are a desirable source for organ repair due
o accessibility for harvest, propensity to propagate in
ulture, and favorable biological profile (32,33). Discovered
s a byproduct of hematopoietic stem cell isolation, deriva-
ion of hMSC is confounded, however, by phenotype
eterogeneity among patients compromising therapeutic
fficacy (34). Here, evaluation of adult stem cells with innate
eparative potential identified traits associated with regen-
rative efficacy, consistent with expression of early and late
c
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s
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ion of cardiac transcription factors is also seen in embryonic
tem cells and is pivotal in their response to a natural
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nvironments to yield tissues emanating from all germinal
ayers (38–40). In vitro, adult stem cells demonstrate a
imited capacity for differentiation, requiring protracted and
ontinuous growth factor exposure to trigger cell fate
Figure 8 Cardiopoietic hMSC Demonstrate Cardiogenic and Va
(A) Human-specific troponin I (green) in the anterior wall of naive- versus cardiopo
Human troponin I staining of naïve versus cardiopoietic hMSC-treated hearts, coun
cycle activation, documented by Ki-67 expression (yellow, arrows), noted in huma
eral vessels from cardiopoietic hMSC-treated hearts demonstrated human-specific
of smooth muscle in vessels from cardiopoietic hMSC-treated but not saline- or na
positive cells in myocardial wall, up-regulated in cardiopoietic versus naïve hMSC-t
between human lamin and smooth muscle actin reveals significant contribution at
group (n  10 in F and G). Star: p  0.05. Abbreviations as in Figures 1, 4, and 6pecification (30,38). In this study, a combinatorial appli- tation of a set of recombinant factors was formulated to
nduce and potentiate the expression of cardiac transcription
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August 24, 2010:721–34 hMSC Cardiopoiesis for Heart Repairesented, the cardiogenic cocktail regimen applied here in
he hMSC model system was distinct from the complex
inetics and morphogen gradients of developmental biology.
et, this cocktail was sufficient to secure across the studied
atient cohort the reparative cardiopoietic phenotype. Further-
ore, there is limited evidence for the capacity of adult hMSC
o execute cardiac fate despite an aptitude for in vivo transdif-
erentiation (12,13,15,36,41). Here, the cocktail-guided car-
iopoietic phenotype demonstrated an acquired capacity for
xtended differentiation yielding adult stem cell–derived sar-
omerogenesis and electromechanical coupling.
The present proof-of-concept study thus establishes a
latform to enhance the benefit of patient-derived stem cells
n treating chronic ischemic cardiomyopathy. Identifying
he molecular properties of reparative hMSC in an ischemic
eart disease patient cohort established criteria consistent
ith an aptitude for cardiac repair. Application of a recom-
inant inductive milieu proved sufficient to guide hMSC
solated from a coronary artery disease cohort into cardio-
oiesis and, thereby, optimize efficacy prior to transplanta-
ion. Cardiogenic cocktail-induced pre-emptive cell fate
pecification ensured safe and lasting functional and struc-
ural benefit following transplantation in the failing isch-
mic heart. Within the healing murine heart, human-
pecific nuclear, sarcomeric, and gap junction proteins
ocumented an active contribution to infarct repair. More-
ver, up-regulation of endogenous stem cells and promotion
f cell cycle activity within the host myocardium indicated a
oncomitant paracrine role in repair (5,34,42,43). Scaled-up
MP production of cardiopoietic hMSC indicated trans-
ational feasibility. Ultimately, the value of this technology
o the patient will require controlled clinical trials.
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